JPRN-UMIN000022956已完成未知
A Phase II study of Ramucirumab beyond disease progression in combination with Irinotecan after failure of weekly Paclitaxel plus Ramucirumab in advanced gastric cancer patients previously treated with fluoropyrimidine and platinum - A Phase II study of Ramucirumab beyond disease progression in combination with Irinotecan after failure of weekly Paclitaxel plus Ramucirumab in advanced gastric cancer patients
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 53
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)with active double cancers excluding carcinoma in situ 2)with pleural fluid, ascites or pericardial effusion that requires drainage 3)with ileus or constipation (>=grade 3) 4)with a histroy of uncontrollable hypertension or acute coronary syndrome in 6 months 5)with active gastrointestinal bleeding in 14 days 6)with severe or uncotrollable complications such as diabetes mellitus, bowel obstruction, jaundice, liver dysfunction, psychological illness and severe infectious disease. 7)with active hepatitis B or C 8)with HIV infection 9)with a history of interstitial pneumonia, pulmonary fibrosis or irradiation pneumonitis 10)with hemorrhagic diathesis or blood coagulation disorder 11)within 28 days after open abdominal or chest surgery or with unrecoverd surgical wounds 12)pregnant and/or nursing women or men who wish to have children in future 13)judged to be unfit to participate in this study by investigater
研究者
相似试验
未知
2 期
A Phase 2 Study of Ramucirumab in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First Line Platinum- or Fluoropyrimidine-Containing Combination Therapy in Japanese PatientsGastric CancerJPRN-jRCT2080222292Eli Lilly Japan K.K.
招募中
2 期
Phase II study of ramucirumab for the patients with advanced hepatocellular carcinoma previously treated with lenvatinibHepatocellular carcinomaJPRN-jRCT1041190083Yamashita Tatsuya33
进行中（未招募）
2 期
Phase II study of ramucirumab in combination with erlotinib for untreated EGFR mutation-positive non-squamous non-small cell lung cancer patients with pleural effusion: RELAY-EffusioEGFR mutation positive advanced non-small cell lung cancerJPRN-jRCTs051210138Kaneda Hiroyasu40
未知
1 期
Phase 1b Study of Ramucirumab in Combination With Fluoropyrimidines and Platinum-Based Agents in Japanese Patients With Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaStomach NeoplasmsJPRN-jRCT2080222764Eli Lilly Japan K.K.
进行中（未招募）
1 期
A pilot study of ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab based therapyadvanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junctionMedDRA version: 21.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: PTClassification code 10062878Term: Gastrooesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-001075-32-DEInstitut für Klinische Krebsforschung IKF GmbH20